Streptococcal pharyngitis in children: a meta-analysis of clinical decision rules and their clinical variables

Flore Le Marechal,1,2 Alain Martinot,1,2,3 Alain Duhamel,1,3,4 Isabelle Pruvost,1,2 François Dubos,1,2,3

ABSTRACT
Objective: To identify the best clinical decision rules (CDRs) for diagnosing group A streptococcal (GAS) pharyngitis in children. A combination of symptoms could help clinicians exclude GAS infection in children with pharyngitis.

Design: Systematic review and meta-analysis of original articles involving CDRs in children. The Pubmed, OVID, Institute for Scientific and Technical Information and Cochrane databases from 1975 to 2010 were screened for articles that derived or validated a CDR on a paediatric population: 171 references were identified.

Setting: Any reference including primary care for children with pharyngitis.

Data extraction: The methodological quality of the articles selected was analysed according to published quality standards. A meta-analysis was performed to assess the statistical performance of the CDRs and their variables for the diagnosis of GAS pharyngitis.

Primary outcome measure: The main criterion was a false-negative rate in the whole population not any worse than that of a rapid diagnostic test strategy for all patients (high sensitivity and low negative likelihood ratio).

Results: 4 derived and 12 validated CDRs for this diagnosis in children. These articles involved 10 523 children (mean age, 7 years; mean prevalence of GAS pharyngitis, 34%). No single variable was sufficient for diagnosis. Among the CDRs, that of Joachim et al had a negative likelihood ratio of 0.3 (95% CI 0.2 to 0.5), resulting in a post-test probability of 13%, which leads to 3.6% false-negative rate among low-risk patients and 10.8% overall, equivalent to rapid diagnostic tests in some studies.

Conclusions: The rule of Joachim et al could be useful for clinicians who do not use rapid diagnostic tests and should allow avoiding antibiotic treatment for the 35% of children identified by the rule as not having GAS pharyngitis. Owing to its poor specificity, such CDR should be used to focus rapid diagnostic tests to children with high risk of GAS pharyngitis to reduce the antibiotic consumption.

ARTICLE SUMMARY

Article focus

- Pharyngitis is a frequent diagnosis in children leading to excessive antibiotic treatments by the inability to distinguish a bacterial from a viral cause of the disease despite the availability of rapid diagnostic test, too rarely done in children with pharyngitis.
- Several studies have analysed the performance of clinical signs and developed clinical decision rules for the diagnosis of group A streptococcal (GAS) pharyngitis in children.
- Through a meta-analysis, this article focus on the methodological quality of these studies and on the value of clinical signs and decision rules that could be helpful to focus rapid diagnostic test to the children with higher risk of GAS pharyngitis.

Key messages

- No symptom considered alone is predictive enough of GAS pharyngitis.
- Some clinical decision rules are performing as well as some rapid diagnostic test to exclude GAS pharyngitis in children, but are not performing enough for the positive diagnosis of GAS pharyngitis, which can lead to a still important antibiotic prescription level.
- Therefore, clinical decision rules could be used to focus rapid diagnostic tests to children with high risk of GAS pharyngitis to reduce the use of antibiotic.

Strength and limitations of this study

- Meta-analysis of all relevant articles, from 1975 to 2010 that analysed the performance of clinical signs and derived or validated clinical decision rules for the diagnosis of GAS pharyngitis in children.
- A decision rule that performed as well as the most rapid diagnostic tests to rule out GAS pharyngitis in children was identified, but has not been validated until now.
- Comparison between studies was limited by methodological weaknesses and heterogeneity between patients.
INTRODUCTION
Acute pharyngitis is one of the most common diseases in the world. It is diagnosed annually in 11 million patients in US emergency departments (ED) and other outpatient settings and is responsible for more than 140 physician office visits and 96 antibiotic prescriptions per 1000 US children under 15 years of age. The group A streptococcal (GAS) form is identified in 20–37% of children with pharyngitis.

The priority over the past 50 years has been the prevention of GAS complications such as local suppurations, invasive infections and acute rheumatic fever (ARF). These complications are rare in industrialised countries; however, among children treated with antibiotics in GAS pharyngitis, less than 1% have supplicative complications, 3/100 000 have invasive infections and 0.08–0.15/100 000 have ARF. ARF rates were declining even before the use of antibiotics because non-rheumatogenic types of streptococci were replacing the rheumatogenic types. The prevention of these complications, however, has induced large-scale prescription of antibiotics, which in turn might induce drug side effects and the emergence of multidrug-resistant organisms owing to pressure on the ecosystem. National guidelines are different from one country to another. To optimise the use of antibiotics, in 2012 the Infectious Diseases Society of America (IDSA) recommended the use of pharyngeal swabs to take samples for bacterial cultures or rapid diagnostic tests (RDTs) because the clinical features alone do not reliably discriminate between GAS and viral pharyngitis. These recommendations have changed some medical practices, but adhesion remains partial. Although diagnostic performances of RDT are good (sensitivity (Se), 85–90%, specificity (Sp), 90–100%), their use is still not widespread, they are offered to less than 50% of patients with pharyngitis and antibiotic prescriptions for children with pharyngitis remain excessive in industrialised countries. Moreover, RDTs are not recommended in practice in all settings internationally. Clinical decision rules (CDRs) have been proposed to help physicians decide whether or not the patient needs further tests (RDTs or culture) or direct antibiotic treatment without further testing. The IDSA recommends the use of such CDRs. Although several authors have suggested CDRs for children, most of these have been validated only partially.

The aim of this study is to conduct the first systematic review, including a meta-analysis, of these CDRs and their variables for the diagnosis of GAS pharyngitis in children, to identify CDRs not any worse than that of an RDT strategy.

METHODS
Search strategy and study selection criteria
This systematic search and quality assessment of studies were performed independently by FLM and FD in August 2010. To identify eligible original articles, we searched four electronic databases: Medline via PubMed, Institute for Scientific and Technical Information (INIST) at article@inist, database now accessible at http://www.Refdoc.fr, the OVID library at http://ovidsp.ovid.com/ and the Cochrane library. In the Medline search, we used the medical subject heading terms ‘pharyngitis’ (MeSH, restricted to major topic) and ‘predictive value of tests’ (MeSH), separated by the Boolean operator AND. Limits were set to specify ‘human’ as the species, ‘all child’ as the age and year of publication from 1975 to 2010, without limits on language of publication. In the other databases, only the MeSH term ‘pharyngitis’ was used and less limits to broaden the research: in INIST via Refdoc, we used the terms ‘pharyngitis’ and ‘children’ from 1975 to 2010; in OVID, we used the terms ‘pharyngitis’, ‘children’ and ‘sensitivity’ with limits set to specify ‘clinical medicine’ as journal subset, and year of publication from 1975 to 2010; in the Cochrane library, we used the term ‘pharyngitis’ alone without limits of dates.

The study selection criterion was the presence of original data used to derive or validate a CDR for predicting GAS pharyngitis in a paediatric population. We reviewed the titles of all articles identified by electronic searches and then the abstracts of those that appeared eligible. Related articles and references in the articles that met the selection criterion were examined to identify references that our electronic research might have missed. Eligible articles were fully reviewed.

Quality criteria for the CDR derivation and validation studies
The quality of the selected articles was determined by applying the methodological standards of Wasson et al and Laupacis et al. Two of the authors (FLM and FD) separately screened each article for the 10 criteria enlisted below. Each criterion applied to GAS pharyngitis was split into 1–4 items (one point per item), as detailed below. Derivation studies could have up to 24 items and validation studies 21. The criteria were: (1) The outcome for the selected articles was GAS pharyngitis. It should have been defined and diagnosed with the gold-standard, a throat culture. The culture technique should have been specified. The test used as the gold-standard should have been assessed blinded, without the knowledge of the value of the predictive variables. (2) The predictive values used in the studies that derived each CDR should have been exhaustively identified and well defined, to facilitate its reproducible use. The choice of the variables should have been explained, and the potentially important variables not included should have been mentioned. The studies that validated CDRs should have used the predictive variables as listed and defined in the derivation. Analyses should have been performed blinded to the outcome. (3) Important patient characteristics should have been described, for example, age, sex ratio and any characteristics that might cause the predictive value to differ within the cohort of patients, such as the prevalence of GAS.
pharyngitis. (4) The study site should have been specified, including the medical setting and the country. (5) The statistics used to derive the CDRs should have been described and justified. The authors should have assessed the possibility that the logistic regression model overfitted the data. (6) The statistical performance of the CDRs should have been described. (7) The reproducibility of the predictive variables and of the CDR should have been assessed. (8) The study should have been prospective, and the CDR should have been fully validated, in accordance with recommendations: derivation study, internal validation, external validation and prospective study of the rule’s impact on clinical behaviour. (9) The CDR should be clinically sensible, easy to use (simple and quick) and should suggest a course of action rather than a probability of disease. (10) The effects of clinical use should have been prospectively measured. This last criterion (impact of the CDR) was evaluated at point 8.

Main criteria of CDR performance
The aim of a CDR strategy is to identify a group of children at low risk of GAS pharyngitis to allow them to avoid antibiotic treatment for these patients and to propose an action (eg, RDT) for patients classified in the high-risk group. A strategy including a CDR was considered useful if it did not increase the false-negative rate in the overall population (high-risk and low-risk patients), compared to an RDT strategy for all patients (figure 1). The RDT strategy (median Se 89%, median Sp 96%) has a median false-negative rate of 11%. Therefore, our criteria for evaluating the performance of each CDR were an Se as good as that of RDTs and a probability of GAS pharyngitis in the low-risk group of patients <11%. This corresponds to a negative likelihood ratio (LR−) of 0.2 or less when the prevalence of GAS pharyngitis is 30%. In the literature, an LR− under 0.2 is considered useful and the median LR− for RDTs is 0.15.

Statistical analysis
After the identification of the CDRs, the entire population was described, in percentages and 95% CI for dichotomous variables and means and ranges for continuous variables. The absence of the raw data prevented us from calculating the SD. The statistical performance of the variables and the CDRs was analysed for paediatric studies only and not in studies that included both children and adults. When possible, we focused on children older than 3 years, because younger children rarely have GAS pharyngitis.

The meta-analysis of the variables included in the CDRs and their validations used the DerSimonian and Laird method. For the Se, Sp, positive and negative predictive values (PPV and NPV), we tested the heterogeneity between studies, applying the LR test. For the OR, positive LR (LR+) and LR−, we used Cochran’s Q test. In analyses with significant heterogeneity or with four or more studies, a random effect model was used to assign the weight of each study. Pooled Se, Sp, PPV, NPV, LR+, LR− and OR with their 95% CIs were calculated for CDRs and their variables.

CDRs in the literature propose different courses of action according to the individual’s clinical risk of GAS pharyngitis. In the selected studies, four CDRs proposed a course of action based on three levels of probability of GAS pharyngitis: high risk (antibiotics), intermediate risk (culture and antibiotics if positive) and low risk (no culture and no antibiotics). One CDR proposed a course of action based on two risk groups, and two CDRs offered four or five risk groups without any courses of action. We chose to identify the CDRs with a useful LR− that would allow us to rule out GAS pharyngitis, as most second-generation RDTs do. Therefore we dichotomised each population into two groups: the low-risk group on one side and the intermediate and high-risk group on the other side (see online supplementary material).

RESULTS
Search strategy results
After excluding duplicates, our search strategy identified 65 references from PubMed, another 89 from INIST, 8 from OVID and 9 from the Cochrane database (see flowchart, figure 2). Reading the titles and abstracts of these 171 references led us to exclude 150 articles that did not meet the inclusion criterion. Complete reading of the remaining 21 articles and reviewing their references, related articles and authors’ publications

---

**Figure 1** Expected performance of a clinical decision rules strategy for group A streptococcal pharyngitis in children compared to the rapid diagnostic test strategy. ATB, antibiotics; CDR, clinical decision rules; RDT, rapid diagnostic test.
identified 15 additional relevant references. Of these 36 references, 18 were excluded because they did not report the derivation or validation of a CDR on a paediatric population. In the 18 articles that fulfilled the inclusion criterion, six studies derived CDRs and 12 validated them in children. Of these 18 studies, the article cited as the source from which the WHO CDR was derived did not provide details about it, and the CDR by Centor et al used for validation in children was derived on adult patients. These two derivation studies were thus screened for methodological quality, but were excluded from the meta-analysis. However, the studies that validated these two CDRs among children were included in the meta-analysis.

Patient characteristics
The 16 studies with data for children included 10 523 children. Eleven studies were conducted in industrialised countries and five in emerging countries. Nine studies were conducted in hospitals or clinics, six in paediatricians’ or general practitioners’ (GPs) offices, and one in GPs’ offices and an ED. Overall, the derivation studies that could be reviewed (n=4) included 963 children (mean number per study 241, range 90–356). All the validation studies (n=12) together included 9560 children (mean number per study 797, range 79–1848). The mean prevalence of GAS pharyngitis was 34% (median 34%, range 24–58%) and did not differ between the derivation and validation studies (33% vs 34%; p=0.54) or between industrialised and emerging countries (34% vs 33%; p=0.30). The children’s mean age was 7 years, 5.9 in the derivation and 7.2 in the validation sets, 5.7 in the emerging and 8.4 in the industrialised countries. The studies used different inclusion criteria: ‘pharyngitis’ (n=5), 23 24 27 35 36 ‘suspected GAS pharyngitis’ (n=4), 22 26 29 34 ‘sore throat’ (n=3) 28 31 33 ‘new upper respiratory tract infection’ (n=2) 21 25 and both ‘new upper respiratory tract infection’ and ‘sore throat’ (n=2). 30 32

Methodological quality for derivation and validation studies
Overall, the derivation studies correctly followed a median of 65% of the quality criteria (range 13–83%). The derivation of WHO’s CDR was not found. The validation studies correctly followed a mean of 69% of these quality criteria (range 43–86%; table 1). One study used an RDT as the gold-standard, 24 and two others used RDTs or throat culture. 29 34 No derivation studies defined a predictive variable; three validation studies did so for at least one variable (ie, cervical lymph node, 25 27 30 abnormal pharynx 25 and exudate 30), but 7/12 validation studies changed a variable (eg, tender node for node, fever ≥38°C for fever >38°C). All studies described the CDRs, although one modified it. 36 No study specifically described whether assessments were blinded, but for validation studies, we considered that a prospective study based on the culture result and without any RDT validated this item. One derivation study simplified a rule without reconducting the statistical analyses. 24 Only one study was retrospective. 34

Performance of the variables
The CDRs considered 17 variables in all, most frequently lymph nodes, exudate, age, fever and cough. The online supplementary materials include a table describing the types of variables by CDR and the details of the CDRs. Table 2 presents the meta-analysis of the statistical performance of these variables. ‘Node >1.5 cm’, ‘sore throat’ and ‘no diarrhoea’ each had an LR− under 0.5. The Se of these three variables exceeded 0.81, and their NPV exceeded 0.72. The statistical performance of
**Table 1** Methodological quality of the selected studies that derived or validated clinical decision rules for the diagnosis of GAS pharyngitis in children

| Quality criteria | Breese*28 | Funamura*25 | Karacan‡27 | Centor†22 | Dagnelie26 | Hal929 | WHO‡35 | Steinhoff | McIsaac†21 | McIsaac22 | McIsaac23 | Edmonson34 | Tanz29 | Attia22 | Attia32 | Smeesters†23 | Joachim24 |
|------------------|-----------|-------------|------------|-----------|------------|--------|--------|----------|----------|----------|----------|------------|--------|---------|--------|-------------|---------|
| Outcome          | Children/total population | 670/670 | 892/892 | 857/857 | 0/234 | 79/558 | 561/561 | MD | 1810/1810 | 90/521 | 167/620 | 454/787 | 1184/1184 | 1848/1848 | 297/297 | 587/587 | 220/220 | 356/356 |
| Outcome          | Study site | Medical setting | Country | GP | Clinic | Hospital | ED | GP | ED | GP | MD | Hospital | Clinic | GP | GP | GP | Clinic | GP | ED | ED | ED | ED |
| Study site       | USA | USA | TUR | USA | NL¶ | USA | MD | EG | BR | EG | CA | CA | CA | USA | USA¶ | USA¶ | BR | BR |
| Statistics       | Described | NC | NC | NC | 1 | NC | NC | 0 | NC | NC | 0 | NC | 1 | NC | NC | NC | NC | 1 | NC | 1 | 1 |
|                  | Logistic regression | NC | NC | NC | 1 | NC | NC | 0 | NC | NC | 0 | NC | 1 | NC | NC | NC | NC | 1 | NC | 1 | 0 |
|                  | Outcome/variable | NC | NC | NC | 0 | NC | NC | 0 | NC | NC | 1 | NC | 0 | 1 | NC | 1 | NC | NC | NC | NC | NC |
|                  | Performance described | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|                  | CDR reproducibility | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
|                  | Development** | 3 | 3 | 3 | 1 | 3 | 3 | 0 | 3 | 3 | 2 | 3 | 3 | 3 | 0 | 3 | 1 | 3 | 2 | 2 |
|                  | CDR practical use | Clinically sensible | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|                  | Easy to use | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|                  | Course of action | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|                  | Total score | 9†† | 12†† | 13†† | 15†† | 14†† | 13†† | 3† | 16†† | 18†† | 20† | 15†† | 16†† | 13†† | 17†† | 16†† | 16†† | 15†† |
|                  | N/24 or N/2155 (%) | (43) | (57) | (62) | (62) | (67) | (13) | (76) | (86) | (83) | (71) | (76) | (62) | (81) | (67) | (76) | (71) | (63) | (63) |

Each study present criterion for patient characteristics and medical setting worth one point each.

*Children >3 years old only.
†Derivation studies.
‡Validated, but adult and paediatric data.
§Estimated with the number of children per age group.
¶Not provided in the articles.
** Development of the rule‡7: derivation study (1 point), internal validation (2 points), external and prospective validation (3 points) and impact of the rule on clinical behaviour (4 points)
††Validation study: 1, validated; 0, not validated, although not specified.
BR, Brazil; Ca, Canada; CDR, clinical decision rule; ED, emergency department; EG, Egypt; GAS, group A streptococcal; GP, general practitioner; HR, Croatia; MD, missing data; NC, not concerned; NL, Netherlands; TUR, Turkey.
| Variables                     | References | Pop (n) | Se (95% CI) | Sp (95% CI) | PPV (95% CI) | NPV (95% CI) | LR+ (95% CI) | LR− (95% CI) | OR (95% CI) |
|-------------------------------|------------|---------|-------------|-------------|--------------|--------------|--------------|--------------|------------|
| **Positive symptoms**         |            |         |             |             |              |              |              |              |            |
| **Tender cervical node**      | 22-24      | 3067    | 45 (42 to 48) | 71 (69 to 73) | 40 (37 to 43) | 76 (74 to 77) | 1.6 (1.5 to 1.8) | 0.7 (0.7 to 0.8) | 2.3 (1.9 to 2.8) |
| Node: any size                | 22-24      | 451     | 81 (73 to 88) | 45 (40 to 50) | 32 (26 to 37) | 89 (83 to 92) | 1.5 (1.3 to 1.7) | 0.4 (0.3 to 0.6) | 3.6 (2.1 to 6.1) |
| Node >1.5 cm                  | 27         | 857     | 40 (36 to 45) | 78 (74 to 81) | 63 (57 to 69) | 58 (54 to 62) | 1.8 (1.3 to 2.5) | 0.8 (0.7 to 0.9) | 2.4 (1.8 to 3.2) |
| Pharynx                       |            |         |             |             |              |              |              |              |            |
| Abnormal pharynx              | 22-24      | 857     | 42 (37 to 46) | 77 (72 to 80) | 63 (57 to 68) | 58 (54 to 62) | 1.8 (1.3 to 2.5) | 0.8 (0.6 to 0.9) | 2.3 (1.7 to 3.1) |
| Pharyngeal exudate            | 22-24      | 1308    | 31 (26 to 36) | 81 (78 to 83) | 37 (32 to 42) | 77 (74 to 79) | 1.6 (1.3 to 1.9) | 0.9 (0.8 to 0.9) | 2.0 (1.5 to 2.6) |
| Swollen tonsils               | 22         | 1481    | 58 (54 to 63) | 57 (54 to 60) | 39 (35 to 42) | 75 (72 to 78) | 1.3 (1.2 to 1.5) | 0.7 (0.7 to 0.8) | 1.9 (1.5 to 2.3) |
| **Fever**                     |            |         |             |             |              |              |              |              |            |
| HF                            | 29-30      | 1006    | 70 (65 to 75) | 32 (29 to 35) | 26 (23 to 30) | 76 (71 to 80) | 1.1 (1.0 to 1.1) | 0.9 (0.7 to 1.1) | 1.2 (0.9 to 1.7) |
| Fever >38°C                   | 22-24      | 2789    | 53 (50 to 56) | 56 (54 to 59) | 40 (37 to 43) | 68 (66 to 71) | 1.1 (1.1 to 1.5) | 0.9 (0.8 to 1.1) | 1.3 (1.1 to 2.2) |
| Fever >38.5°C                 | 23         | 576     | 64 (57 to 70) | 28 (24 to 33) | 28 (24 to 32) | 64 (57 to 70) | 0.9 (0.8 to 1.0) | 1.2 (1.0 to 1.6) | 0.7 (0.5 to 1.1) |
| HF or >38°C                   | 22-24      | 3795    | 56 (54 to 60) | 49 (47 to 51) | 36 (33 to 37) | 70 (67 to 72) | 1.1 (1.1 to 1.3) | 0.9 (0.8 to 1.1) | 1.3 (1.1 to 1.9) |
| Headache                      | 22-24      | 1730    | 51 (48 to 55) | 64 (61 to 67) | 48 (44 to 51) | 67 (64 to 70) | 1.3 (1.1 to 1.5) | 0.9 (0.8 to 1.0) | 1.5 (1.2 to 2.2) |
| Sore throat                   | 27         | 2041    | 86 (83 to 88) | 27 (25 to 30) | 43 (41 to 46) | 75 (71 to 78) | 1.2 (1.1 to 1.2) | 0.5 (0.4 to 0.6) | 2.4 (2.0 to 3.2) |
| Scarletinal rash              | 22         | 297     | 14 (8 to 23)  | 97 (93 to 98) | 63 (41 to 81) | 74 (68 to 79) | 4.7 (2.1 to 10.5) | 0.9 (0.8 to 1.0) | 4.8 (1.8 to 12.7) |
| Petechia on the palate        | 22-24      | 873     | 20 (16 to 25) | 88 (86 to 91) | 42 (34 to 51) | 72 (69 to 75) | 1.8 (1.3 to 2.5) | 0.9 (0.9 to 1.0) | 2.1 (1.5 to 2.9) |
| Sudden onset                  | 23         | 576     | 32 (26 to 39) | 69 (65 to 74) | 31 (25 to 38) | 70 (65 to 74) | 1.1 (0.8 to 1.4) | 1.0 (0.9 to 1.1) | 1.1 (0.7 to 1.6) |
| **Negative symptoms**         |            |         |             |             |              |              |              |              |            |
| No cough                      | 23-24      | 3627    | 65 (63 to 68) | 55 (53 to 57) | 43 (41 to 45) | 75 (73 to 77) | 1.5 (1.4 to 1.7) | 0.6 (0.6 to 0.7) | 2.4 (2.1 to 3.1) |
| No rhinorhoea                 | 22-24      | 3365    | 71 (69 to 74) | 50 (48 to 52) | 43 (41 to 45) | 76 (74 to 79) | 1.3 (1.3 to 1.5) | 0.6 (0.6 to 0.8) | 2.2 (1.9 to 3.3) |
| No abdominal pain             | 22-24      | 873     | 69 (64 to 75) | 29 (26 to 33) | 30 (26 to 33) | 69 (64 to 74) | 1.0 (0.9 to 1.1) | 1.1 (0.8 to 1.3) | 1.0 (0.7 to 1.3) |
| No diarrhoea                  | 23         | 1433    | 94 (92 to 95) | 12 (10 to 14) | 43 (40 to 45) | 72 (65 to 79) | 1.1 (1.0 to 1.1) | 0.5 (0.3 to 0.7) | 2.3 (1.5 to 3.4) |
| No conjunctivitis             | 23         | 576     | 100 (NC to 100) | 6 (4 to 8) | 32 (28 to 36) | 100 (NC to 100) | 1.0 (1.0 to 1.0) | NC | NC |
| No viral exanthema            | 23         | 576     | 88 (83 to 92) | 2 (1 to 3) | 28 (25 to 32) | 22 (11 to 38) | 1.0 (1.0 to 1.0) | 0.4 (3.2 to 21.6) | 0.1 (0.0 to 0.3) |

PPV and NPV should be interpreted with the prevalence of the disease in each study, available in Table 1.

HF, history of fever; LR+, positive likelihood ratio; LR−, negative likelihood ratio; n, number of children; NC, not calculable; NPV, negative predictive value; Pop, population; PPV, positive predictive value; Se, sensitivity; Sp, specificity.
‘Node >1.5 cm’ was not reproducible with the other ‘node’ variables. ‘Scarlatiniform rash’ had the highest LR+ (4.7) and OR (4.8). All other LR+ were less than 2.

Performance of the CDRs

After meta-analysis of the validation studies, three rules had high Se (99%, 95% and 88%) and NPVs (87–88%). However, the rules of McIsaac et al and Attia et al were not discriminative (Sp, 14% and 4%), and were negative for only 10% and 3% of the population, respectively (table 3). These rules were therefore not useful in clinical practice. The rule tested by Joachim et al had one of the best LR− (table 3), with a value of 0.3 (95% CI 0.2 to 0.5), which should help clinicians to rule out the diagnosis of GAS pharyngitis. Application of this CDR brought the probability of GAS pharyngitis down from 34% to 13% when the score of the CDR is negative (figure 3). The rule of Joachim et al also had the best performance, with an Se of 88%, a post-test probability of 13% in 28% of the low-risk patients, and an Sp of 35% (95% CI 30 to 40). This rule leads to a 3.6% false-negative rate in this low-risk population and 11.5% overall with an RDT strategy for the intermediate and high-risk patient groups and on the assumption that the RDT Se was 89%.

DISCUSSION

The large number of studies and CDRs proposed for the diagnosis of GAS pharyngitis is the evidence of physicians’ desire to improve their management of this common disease and to limit antibiotic prescriptions, bacterial resistance and costs. Our study shows how difficult it is to develop and validate an effective and useful CDR. We identified 16 articles that described the derivation or validation of seven CDRs for the diagnosis of GAS pharyngitis in children. The meta-analysis confirmed, as others recently,41 that symptoms alone were not sufficient to rule out this diagnosis. Examination of the statistical performance of the variables included in the CDRs showed that none had a significant positive (>5) or negative (<0.2) LR.42 Two CDRs brought the post-test probability of GAS pharyngitis to around 10%.22 24 Only the CDR of Joachim et al was considered useful for clinical use to exclude GAS pharyngitis.

The poor performance of each of these variables requires comment. It might be owing to the low Sp of some signs (such as rhinorrhoea and cervical nodes), their subjectivity in children (sore throat) or a lack of definition. For these reasons, several variables might have been recorded differently from study to study and possibly within some studies. Because the individual variables predict GAS pharyngitis so poorly, researchers have suggested combining potential predictive variables within a CDR. Our systematic review of standards for the derivation of CDRs,37 38 however, shows that none of the studies followed all of the methodological quality criteria, in particular, the studies that derived CDRs did
performed the best but has not been externally validated yet and requires the collection of nine variables for its application, which may limit its use in practice. Since CDRs were more useful than individual symptoms, they might help the clinicians who do not use RDTs in ruling out the diagnosis of GAS pharyngitis. The IQR of LR for second-generation RDTs varies from 0.07 to 0.19.14 Thus the probability of GAS pharyngitis would have been reduced from 34% to a post-test probability of less than 10% for most RDTs.14 15 Compared to this full RDT strategy, the CDR of Joachim et al leads to a maximum 11.5% false-negative rate globally; 3.6% in the low-risk group of patients (28%) and 7.9% in the intermediate-risk and high-risk group (72%), if we assume an RDT strategy with 89% Se (probably an underestimate in this group). Nevertheless, none of the CDRs included in this study reached the level of performance required to bring both the probability of GAS pharyngitis and the risk of a false-negative test to less than 10%, as most RDTs do.

Our study has some limitations. Because of the lack of access to individual data, except from two authors who provided the complete set of data from their derivation study,23 24 we could only perform a meta-analysis of the pooled data. Moreover, the populations involved in our analysis were heterogeneous and difficult to compare. These differences concerned (1) the objective of the study, since some studies sought to validate a CDR while others tested RDTs35 or serological titres28; (2) the inclusion criteria, which differed between CDRs and even within the same CDR and (3) the mean age of the patients, which might influence the prevalence of the disease and the type of symptoms.27 The prevalence of the disease varied and could double between studies, as a result of differences in patients’ ages31 or study sites or because of a short study period when GAS might be more or less prevalent.19 22 25 Although prevalence did not influence Se, Sp or the LRs of the variables, it might influence the choice of variables for building the CDR, especially when methodological standards are not adhered to closely. A spectrum bias is possible if reference standards were not performed in all patients of the included studies. Variables might be defined differently between studies of the same CDR, and one CDR might suggest a different course of action in different studies.36 Another important variation may come from the definition of the disease (pharyngitis), which was not provided in the studies and which varies between countries.12 45 We had to create artificial risk groups and courses of action for three CDRs, although they had not been derived for that purpose; our results thus cannot reflect exactly the performance of each risk group. Finally, a review was recently published on this subject but focused the literature research on the signs and symptoms of pharyngitis, when we focused it on CDRs. Findings were slightly different in terms of articles reviewed and not different in terms of performance of individual variables.41 The CDR by Attia et al was

---

Figure 3 Post-test probability of the clinical decision rules (CDRs) for the low-risk group of patients compared with the performance of the rapid diagnostic tests on Fagan’s nomogram. The pretest probability considered (prevalence of the disease) was 34%.
identified by their systematic research but not the one by Joachim et al.

Lastly, we must question whether physicians will use a CDR at all for a well known and usually banal disease. It might be useful for countries where the RDT use is not recommended in current practice.18 It might also well interest the 50% of physicians who do not use RDTs at all.13 16 17 It will do so only, however, if the CDR produces accurate results, is useful, is well validated and is easy to use. The heterogeneity of patients between studies might necessitate a validation and a comparison of available CDRs in a single paediatric population. Our results showed that one CDR has a performance that did not produce a false-negative rate for GAS pharyngitis higher than that of the RDT strategy.20 The rule has only 35% Sp; but its use could avoid about six millions of antibiotic prescriptions in American children (<15 years old) when considering that almost 20% of the 300 million people in the USA are under 15 and that 96/10002 receive an antibiotic for pharyngitis. However, an external validation in different resource settings may be warranted before generalisation. After validation, this CDR might help physicians focus RDTs on children at higher risk of GAS pharyngitis and therefore decrease antibiotic prescriptions for children in the low-risk group.

Contributors Study concept and design, and study supervision were carried out by FLM, FD, IP and AM. Acquisition of data was carried out by FLM. Analysis and interpretation of data, and critical revision of the manuscript for important intellectual content were carried out by FLM, FD, AD, IP and AM. Drafting of the manuscript was carried out by FLM, FD and AD. Le Marechal and Dubos (guarantor) have full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

REFERENCES

1. Choby BA. Diagnosis and treatment of streptococcal pharyngitis. Am Fam Physician 2009;79:383–90.
2. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002;287:3096–102.
3. Danchin MH, Roger S, Kelpie L, et al. Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics 2007;120:950–7.
4. Shaikh N, Leonard E, Martin JM. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. Pediatrics 2010;126:e597–64.
5. Ebell MH, Smith MA, Barry HC, et al. The rational clinical examination. Does this patient have strep throat? JAMA 2000;284:2912–18.
6. Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal disease in Sweden. Clin Infect Dis 2007;45:450–8.
7. Olvier C, Portier H, Cohen R, et al. Acute rheumatic fever: results of a national survey (1995–1997). Bull Epidemiol Hebdom 1999;12:45–7.
8. Van der Helm-van Mil AH. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Curr Opin Rheumatol 2002;14:42–7.
9. Shulman ST, Stolerman G, Beall B, et al. Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis 2006;42:441–7.
10. Grivea IN, Ali-Lahham A, Kalpounis GD, et al. Resistance to erythromycin and tetracycline in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillitis/pharyngitis: phenotypic and genotypic analysis. Antimicrob Agents Chemother 2006;50:256–61.
11. Matthys J, De Meyere M, Van Driel ML, et al. Differences among international pharyngitis guidelines: not just academic. Ann Fam Med 2007;5:436–43.
12. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012;55:1279–82.
13. Linder JA, Bates DW, Lee GM, et al. Antibiotic treatment of children with sore throat. JAMA 2005;294:2315–22.
14. Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A streptococci. Clin Microbiol Rev 2004;17:571–80.
15. Webb KH. Does culture confirmation of high-sensitivity rapid streptococcal tests make sense? A medical decision analysis. Pediatrics 1998;101:E2.
16. Park SY, Geesey J, Tanz RR, et al. Physicians’ management of children and adolescents with acute pharyngitis. Pediatrics 2006;117:1871–8.
17. Paquet M, Assenay N, Lex C, et al. Use of rapid diagnostic tests of tonsillitis in medical practice. Survey conducted from November 2006 to January 2007 in Pays de la Loire (France). Presse Med 2010;39:a77–85.
18. Tan T, Little P, Stokes T. Guideline Development Group. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ 2008;337:a437.
19. Centor RM, White D, Tannenbaum D, et al. The diagnosis of strep throat in adults in the emergency room. Med Decis Making 1981;1:239–46.
20. WHO. The management of acute respiratory infections in children: practical guidelines for outpatient care. Geneva: World Health Organization, 2007. http://www.who.int/catco/20Catalogue/H%20-%20CDC(H-11).pdf (accessed 15 Feb 2012).
21. McIsaac WJ, Kellner JD, Aufricht P, et al. Antibiotic use in the management of group A streptococcal pharyngitis in children. Clin Infect Dis 2009;49:1138–49.
22. Aumann K, Mozaffarian DA, Steinhoff MC, et al. A national survey of antibiotic use in children with pharyngitis. Pediatrics 2013;132:e593–602.
23. Centor RM, Watkins LR, Scholtz DO, et al. Multivariate predictive models for group A beta-hemolytic streptococcal pharyngitis in children. Acad Emerg Med 1999;6:8–13.
24. Smesteea PR, Campo D Jr, Van Meldereb L, et al. Pharyngitis in low-resource settings: pragmatic clinical approach to reduce unnecessary antibiotic use. Pediatrics 2010;126:e608–14.
25. Breese BB. A simple scorecard for the tentative diagnosis of streptococcal pharyngitis. Am J Dis Child 1977;131:514–17.
26. Funamura JL, Berkowitz CD. Applicability of a scoring system in the diagnosis of streptococcal pharyngitis. J Pediatr 1983;22:622–6.
27. Karacan M, Kanekelleoglu C, Orbak Z. Diagnosis of group A beta-hemolytic Streptococcus using the Breese clinical scoring system. South Med J 2007;100:1192–7.
28. Dagnelle CF, Bartelink ML, Van der Graaf Y, et al. Towards a better diagnosis of throat infections (with group A beta-haemolytic streptococcus) in general practice. Br J Gen Pract 1998;48:959–62.
29. Hall MC, Klee B, Gonzales R, et al. Spectrum bias of a rapid antigen detection test for group A beta-hemolytic streptococcal pharyngitis in a pediatric population. Pediatrics 2004;114:182–6.
30. Steinhoff MC, Abd el Khalek MK, Khallaf N, et al. Effectiveness of clinical guidelines for the presumptive treatment of streptococcal pharyngitis in Egyptian children. Lancet 1997;350:918–21.
31. Rimoin AW, Hamza HS, Vince A, et al. Evaluation of the WHO clinical decision rule for streptococcal pharyngitis. Arch Dis Child 2005;90:1066–70.
32. McIsaac WJ, Goel V, To T, et al. The validity of a sore throat score in family practice. CMAJ 2000;163:811–15.
33. McIsaac WJ, Kellner JD, Aufricht P, et al. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA 2004;291:1587–95.
34. Edmonson MB, Farwell KR. Relationship between the clinical likelihood of group A streptococcal pharyngitis and the sensitivity of a rapid antigen-detection test in a pediatric practice. Pediatrics 2005;115:280–5.
35. Tanz RR, Gerber MA, Kabat W, et al. Performance of a rapid antigen-detection test and throat culture in community pediatric
36. Attia MW, Zaoutis T, Klein JD, et al. Performance of a predictive model for streptococcal pharyngitis in children. Arch Pediatr Adolesc Med 2001;155:687–91.
37. Wasson JH, Sox HC, Neff RK, et al. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985;313:793–9.
38. Laupacis A, Sekar N, Stell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 1997;277:488–94.
39. McGinn TG, Guyatt GH, Wyer PC, et al. Users’ guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA 2000;284:79–84.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
41. Shaikh N, Swaminathan N, Hooper EG. Accuracy and precision of the signs and symptoms of streptococcal pharyngitis in children: a systematic review. J Pediatr 2012;160:487–93.e3.
42. Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid?. Evidence-Based Medicine Working Group. JAMA 1994;271:389–91.
43. Breese BB, Disney FA. The accuracy of diagnosis of beta streptococcal infections on clinical grounds. J Pediatr 1954;44:670–3.
44. Wald ER, Green MD, Schwartz B, et al. A streptococcal score card revisited. Pediatr Emerg Care 1998;14:109–11.
45. Agence française de sécurité sanitaire des produits de santé. Antibiothérapie par voie générale en pratique courante dans les infections respiratoires hautes de l’adulte et de l’enfant. 2005. http://www.afssaps.fr/var/afssaps_site/storage/original/application/e7545c16aaf2690369c724cf8639b65.pdf (accessed 29 Jul 2011).